[1]张驰原,吴智鸿,李旭平,等.新型口服抗凝药物拮抗剂的研究进展[J].心血管病学进展,2016,(2):156-159.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.015]
　ZHANG Chiyuan,WU Zhihong,LI Xuping,et al.Progression of Specific Antidotes for New Oral Anticoagulants[J].Advances in Cardiovascular Diseases,2016,(2):156-159.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.015]
点击复制

新型口服抗凝药物拮抗剂的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2016年2期
页码:
156-159
栏目:
综述
出版日期:
2016-04-20

文章信息/Info

Title:
Progression of Specific Antidotes for New Oral Anticoagulants
作者:
张驰原; 吴智鸿; 李旭平; 综述; 刘启明; 审校
中南大学湘雅二医院心血管内科,湖南 长沙 410011
Author(s):
ZHANG Chiyuan; WU Zhihong; LI Xuping; LIU Qiming
Department of Cardiology, The Second Xiangya Hospital, Changsha 410011, Hunan, China
关键词:
新型口服抗凝药;  拮抗剂;  Idarucizumab;  Andexanetalfa;  Aripazine
Keywords:
New oral anticoagulants;  Specific antidotes;  Idarucizumab;  Andexanetalfa;  Aripazine
分类号:
R973+2
DOI:
10.16806/j.cnki.issn.1004-3934.2016.02.015
文献标志码:
A
摘要:
华法林曾作为唯一的口服抗凝剂在临床应用上已逾60年。近年来,一批新型口服抗凝药物有取代华法林用于血栓栓塞性疾病和非瓣膜性心房颤动脑卒中预防和治疗的趋势,新型口服抗凝药物较华法林的优势在其药代动力学的可预测性,较少的食物与药物相互作用以及无需常规监测凝血指标等。虽然新型口服抗凝药物半衰期较短,多数情况下无需特异性拮抗剂,但在大出血或紧急手术时,缺乏拮抗剂使处理更为困难。目前,一些关于新型口服抗凝药物潜在特异性拮抗剂已在早期临床试验中表现出良好的疗效和安全性,现就其研究进展做简要综述。
Abstract:
Warfarin has been the only available oral anticoagulant for more than 60 years.During the past decade, several new oral anticoagulants(NOACs)have been approved for the prophylaxis and treatment of thromboembolism and stroke prevention in patients with non-valvular atrial fibrillation, which will be treated as a substitute for warfarin.These new agents have several advantages over warfarin including; more predictable pharmacokinetics and pharmacodynamics, fewer food and drug interactions and a lack of need for routine coagulation monitoring.Specific antidotes for NOACs may not be needed in most situations due to their short half-life, yet the absence of antidotes for these agents may make the situation worse, especially in emergency situations such as life-threatening major bleeding or urgent surgery.Several potentially specific antidotes for NOACs have been developed and have shown promising in early clinical trials, evaluating their efficacy and safety.In this review, the progress made in developing specific antidotes for NOACs is summarized.

参考文献/References:

[1] Giugliano RP,Ruff CT,Braunwald E,et al.Edoxaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2013,369(22):2093-2104.
[2] Szczerba E.Summary of the article: rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J].Kardiol Pol, 2012,70(1):102-103.
[3] Granger CB,Alexander JH,McMurray JJ,et al.Apixaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med, 2011,365(11):981-992.
[4] Connolly SJ,Ezekowitz MD,Yusuf S,et al.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2009,361(12):1139-1151.
[5] Khadzhynov D,Wagner F,Formella S,et al.Effective elimination of dabigatran by haemodialysis.A phase I single-centre study in patients with end-stage renal disease[J].Thromb Haemost,2013,109(4):596-605.
[6] van Ryn J,Stangier J,Haertter S,et al.Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor:interpretation of coagulation assays and reversal of anticoagulant activity[J].Thromb Haemost,2010,103(6):1116-1127.
[7] Fukuda T,Honda Y,Kamisato C,et al.Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents[J].Thromb Haemost,2012,107(2):253-259.
[8] Canelo R,Hakim NS,Ringe B.Experience with hystidine tryptophan ketoglutarate versus University Wisconsin preservation solutions in transplantation[J].Int Surg,2003,88(3):145-151.
[9] Levi M,Levy JH,Andersen HF,et al.Safety of recombinant activated factor Ⅶ in randomized clinical trials[J].N Engl J Med, 2010,363(19):1791-1800.
[10] Schiele F,van Ryn J,Canada K,et al.A specific antidote for dabigatran: functional and structural characterization[J].Blood, 2013,121(18):3554-3562.
[11] Toth J,Gan GF,van Ryn J,et al.Reversal of Dabigatran's Anticoagulant Activity in the Monkey by a Specific Antidote and Pharmacokinetic and Pharmacodynamic Modeling[J].Stroke, 2013,44(2):1.
[12] Glund S,Stangier J,Schmohl M,et al.Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers:a randomised, placebo-controlled, double-blind phase 1 trial[J].Lancet, 2015,15(3):13-15.
[13] Van RJ,Schmoll M,Pillu H,et al.Effect of dabigatran on the ability to generate fibrin at a wound site and its reversal by idarucizumab, the antidote to dabigatran, in healthy volunteers:an exploratory marker of blood loss[J].Circulation,2014,130(20):463-466.
[14] Lu G,DeGuzman FR,Hollenbach SJ,et al.A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa[J].Nat Med,2013,19(4):446-451.
[15] Hollenbach SJ,Lu G,DeGuzman F,et al.Andexanet-alfa and PER977(Aripazine)correct blood loss in a rabbit liver laceration model, only andexanet reverses markers of fXa-mediated anticoagulation[J].Circulation,2014,130(25):27-30.
[16] Crowther M,Mathur V,Kitt M,et al.A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanetalfa(PRT064445), an antidote for fXa inhibitors[J].Blood,2014,124(21):1.
[17] Crowther M,Kitt M,Lorenz T,et al.A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors[J].Blood,2013,11(2):30.
[18] Ansell JE,Bakhru SH,Laulicht BE,et al.Use of PER977 to reverse the anticoagulant effect of edoxaban[J].N Engl J Med, 2014,371(22):2141-2142.
[19] Hackam DG,Redelmeier DA.Translation of research evidence from animals to humans[J].JAMA,2006,296(14):1731-1732.
[20] van Ryn J,Strangier J,Haertter S,et al.Dabigatran etexilate —a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity[J].Thromb Haemost,2010,103:1116-1127.
[21] Reilly PA,Lehr T,Haertter S,et al.The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial(Randomized Evaluation of Long-Term Anticoagulation Therapy)[J].J Am Coll Cardiol,2014,63(4):321-328.

相似文献/References:

[1]王璐 李耀东.TAVR合并心房颤动抗凝策略的研究进展[J].心血管病学进展,2022,(8):695.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.007]
　WANG Lu,LI Yaodong.Anticoagulation Strategy in Patients After TAVR Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(2):695.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.007]
[2]向珍贤 罗素新 黄毕.瓣膜性房颤和非瓣膜性房颤的区别和抗凝策略的差异[J].心血管病学进展,2023,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.010]
　XIANG ZhenxianLUO SuxinHUANG Bi.The Difference of Definition and Anticoagulation Therapy Strategies Between Valve and Non-valve Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2023,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.010]

备注/Memo

备注/Memo:
作者简介:张驰原(1990—),住院医师,在读硕士,主要从事心血管介入治疗研究。Email:zcydsg@163.com 通信作者:刘启明(1969—),主任医师,教授,医学博士,博士生导师,主要从事心血管疾病尤其介入心脏病学临床、科研与教学工作。Email:qimingliu@126.com
更新日期/Last Update: 2016-03-25